XLO Historical PE Ratio image   This XLO PE ratio history page last updated 11/10/2022
XLO Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/9/2022
2.29-0.72-2.88NA
Q2 2022
8/9/2022
2.42-0.90-3.60NA
Q1 2022
5/12/2022
3.01-0.78-3.12NA
Q4 2021
3/1/2022
10.89-0.98-3.92NA
Q3 2021
12/2/2021
14.19-21.27-85.08NA
XLO PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/9/2022
2.29-0.72-3.38NA
Q2 2022
8/9/2022
2.42-0.90-23.93NA
Q1 2022
5/12/2022
3.01-0.78NANA
Q4 2021
3/1/2022
10.89-0.98NANA
Q3 2021
12/2/2021
14.19-21.27NANA
How should the XLO historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Xilio Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this XLO Historical PE Ratio page.

What is the average historical PE for XLO based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The XLO historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for XLO based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The XLO historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the XLO Historical PE Ratio information for Xilio Therapeutics' stock. The average XLO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average XLO historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this XLO historical PE result, against the recent PE: when this page was posted on 11/9/2022, the most recent closing price for XLO had been 2.29, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on XLO or any other given stock, valuation analysis for XLO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Xilio Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for XLO. Thanks for visiting, and the next time you need to research XLO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: DIN YTD Return, ABMD shares outstanding history, Top Ten Hedge Funds Holding PTNR.

 

XLO Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.